Skip to main content

Advertisement

SpringerLink
Log in

Screening and Surveillance for Barrett’s Esophagus: Is It Cost-Effective?

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The cost-effectiveness of screening and surveillance for Barrett’s esophagus continues to evolve as the incidence of esophageal adenocarcinoma increases, biomarkers enhance the identification of individuals at highest risk for developing cancer, and endoscopic eradication of Barrett’s esophagus improves. Screening to detect Barrett’s esophagus may be cost-effective in selected high-risk groups based on age, race, sex and other factors such as symptoms of heartburn. Currently, endoscopic eradication therapy for Barrett’s esophagus and high-grade dysplasia is a cost-effective intervention, while endoscopic therapy for non-dysplastic Barrett’s esophagus is not a cost-effective strategy. As diagnosis of low-grade dysplasia improves, endoscopic eradication therapy may also prove to be a cost-effective intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol.. 2016;111:30–50. quiz 51.

    Article  PubMed  CAS  Google Scholar 

  2. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.

    Article  PubMed  Google Scholar 

  3. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172–1177.

    Article  PubMed  CAS  Google Scholar 

  4. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–1258.

    Article  PubMed  CAS  Google Scholar 

  5. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339–1341.

    Article  PubMed  CAS  Google Scholar 

  6. Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:51–63.

    Article  PubMed  Google Scholar 

  7. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.

    Google Scholar 

  8. Laureys S, Pellas F, Van Eeckhout P, et al. The locked-in syndrome: what is it like to be conscious but paralyzed and voiceless? In: Laureys S, ed. Progress in brain research, vol. 150. Amsterdam: Elsevier; 2005:495–611.

    Google Scholar 

  9. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis : methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford University Press; 2000.

    Google Scholar 

  10. Box GEP, Draper NR. Empirical model-building and response surfaces. New York: Wiley; 1987.

    Google Scholar 

  11. Saxena N, Inadomi JM. Effectiveness and cost-effectiveness of endoscopic screening and surveillance. Gastrointest Endosc Clin N Am. 2017;27:397–421.

    Article  PubMed  Google Scholar 

  12. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–186.

    Article  PubMed  Google Scholar 

  13. Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc. 2003;57:311–318.

    Article  PubMed  Google Scholar 

  14. Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2004;2:868–879.

    Article  PubMed  Google Scholar 

  15. Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett’s esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5:312–318.

    Article  PubMed  Google Scholar 

  16. Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett’s esophagus. Clin Gastroenterol Hepatol. 2007;5:319–325.

    Article  PubMed  Google Scholar 

  17. Gupta N, Bansal A, Wani SB, Gaddam S, Rastogi A, Sharma P. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011;74:610–624. e612.

    Article  PubMed  Google Scholar 

  18. Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144:62–73. e66.

    Article  PubMed  Google Scholar 

  19. Heberle CR, Omidvari AH, Ali A, et al. Cost effectiveness of screening patients with gastroesophageal reflux disease for barrett’s esophagus with a minimally invasive cell sampling device. Clin Gastroenterol Hepatol. 2017;15:1397–1404.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Comay D, Blackhouse G, Goeree R, Armstrong D, Marshall JK. Photodynamic therapy for Barrett’s esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol. 2007;21:217–222.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett’s esophagus with high grade dysplasia. Dig Dis Sci. 2003;48:1273–1283.

    Article  PubMed  Google Scholar 

  22. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis. Gut. 2004;53:1736–1744.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2004;60:739–756.

    Article  PubMed  Google Scholar 

  24. Boger PC, Turner D, Roderick P, Patel P. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2010;32:1332–1342.

    Article  PubMed  CAS  Google Scholar 

  25. Hu Y, Puri V, Shami VM, Stukenborg GJ, Kozower BD. Comparative effectiveness of esophagectomy versus endoscopic treatment for esophageal high-grade dysplasia. Ann Surg. 2016;263:719–726.

    Article  PubMed  Google Scholar 

  26. Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143:567–575.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136:2101–2114. e2101–2106.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Pohl H, Sonnenberg A, Strobel S, Eckardt A, Rosch T. Endoscopic versus surgical therapy for early cancer in Barrett’s esophagus: a decision analysis. Gastrointest Endosc. 2009;70:623–631.

    Article  PubMed  Google Scholar 

  29. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249.

    Article  PubMed  Google Scholar 

  30. von Rahden BH, Stein HJ, Weber A, et al. Critical reappraisal of current surveillance strategies for Barrett’s esophagus: analysis of a large German Barrett’s database. Dis Esophagus. 2008;21:685–689.

    Article  Google Scholar 

  31. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.

    Article  PubMed  Google Scholar 

  32. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:U1179–U1590.

    Article  Google Scholar 

  33. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50:23–26.

    Article  PubMed  CAS  Google Scholar 

  34. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988;19:166–178.

    Article  PubMed  CAS  Google Scholar 

  35. Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2015;64:864–871.

    Article  PubMed  CAS  Google Scholar 

  36. Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. 2013;77:190–199.

    Article  PubMed  Google Scholar 

  37. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.

    Article  PubMed  PubMed Central  Google Scholar 

  38. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030–1036.

    Article  PubMed  Google Scholar 

  39. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.

    Article  PubMed  CAS  Google Scholar 

  40. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–244. quiz e232.

    Article  PubMed  Google Scholar 

  41. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378.

    Article  PubMed  CAS  Google Scholar 

  42. di Pietro M, Alzoubaidi D, Fitzgerald RC. Barrett’s Esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver. 2014;8:356–370.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2005;22:135–146.

    Article  PubMed  CAS  Google Scholar 

  44. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. Cancer Res. 2001;61:8284–8289.

    PubMed  CAS  Google Scholar 

  45. Alvi MA, Liu X, O’Donovan M, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin Cancer Res. 2013;19:878–888.

    Article  PubMed  CAS  Google Scholar 

  46. Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009;69:4112–4115.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Kaz AM, Wong CJ, Luo Y, et al. DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics. 2011;6:1403–1412.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45:478–486.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–2848.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071–3083.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc.. 2014;79:242–256. e246.

    Article  PubMed  Google Scholar 

  54. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett’s esophagus. J Natl Cancer Inst. 2004;96:316–325.

    Article  PubMed  CAS  Google Scholar 

  55. Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C. Statins and aspirin for chemoprevention in Barrett’s esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila). 2014;7:341–350.

    Article  CAS  Google Scholar 

  56. Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology. 2003;124:1758–1766.

    Article  PubMed  Google Scholar 

  57. Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy. 2009;41:400–408.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356424, Seattle, WA, 98195, USA

    John M. Inadomi & Nina Saxena

Authors
  1. John M. Inadomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nina Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John M. Inadomi.

Ethics declarations

Conflict of interest

John M. Inadomi is on the scientific advisory board for Cernostics, and receives research support from Ninepoint.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Inadomi, J.M., Saxena, N. Screening and Surveillance for Barrett’s Esophagus: Is It Cost-Effective?. Dig Dis Sci 63, 2094–2104 (2018). https://doi.org/10.1007/s10620-018-5148-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-018-5148-7

Keywords

Search

Navigation